Sex: M
Vaccine: MENB, MNQ
Symptoms: Off label use, Product administered to patient of inappropriate age
Clinical narrative: Menactra: given to each patient other that they are currently around 60 years of age, with no reported adverse event; Initial information received  on 28-Jul-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves Adult male patient who while receiving vaccines BEXSERO and MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] and it was reported that menactra: given to each patient other that they are currently around 60 years of age,with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included OCTINOXATE, OCTOCRILENE (SOLARIS) for Immunisation.  On an unknown date, the patient received a 1 dosage form of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE lot number not reported via unknown route in unknown administration site as prophylactic vaccination.  On an unknown date, the patient received a  1 dosage form of  suspect BEXSERO not produced by Sanofi Pasteur,lot number not reported via unknown route in unknown administration site as prophylactic vaccination. Lot numbers were requested.  On an unknown date the  menactra: given to each patient other that they are currently around 60 years of age,with no reported adverse event (product administered to patient of inappropriate age) same day following the administration of all suspect vaccines.  Caller stated she has 2 male patients currently on Solaris and that both patients will be going to Ultomiris, which would pose an increased risk for meningitis. Caller stated both patients received 1 dose of MENACTRA and 1 dose of Bexsero 2 years ago and that they never received their second doses. Caller stated she thinks that both patients need to repeat the entire series because the guidelines state that a booster was recommended at different years after vaccination but that these 2 patients were never fully vaccinated. Caller stated it is unknown why neither patient received their second dose. Caller stated: Can you just confirm that they need to have the full series and the ACWY (full form not reported) says at least 8 weeks after day zero, because if you just get 1 dose of those, it's really not truly a booster since they were not fully vaccinated. Off label use for Menactra due to age.There was no specific information on each patient other that they are currently around 60 years of age and received the dose within the past 2 to 3-years. The patients are immunocompromised and following guidelines for the medication Ultomiris (ravulizumab-cwvz) and being at higher risk for meningitis.  Action taken  was not applicable.  It was not reported if the patient received a corrective treatment for the event.  At time of reporting, the outcome was Unknown for the event.    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.